{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:43:41Z","timestamp":1784630621821,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jpba.2019.113027","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T21:24:16Z","timestamp":1575408256000},"page":"113027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Hydrophobic interaction chromatography (HIC) method development and characterization of resolved drug-load variants in site-specifically conjugated pyrrolobenzodiazepine dimer-based antibody drug conjugates (PBD-ADCs)"],"prefix":"10.1016","volume":"179","author":[{"given":"Thamara","family":"Janaratne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Leanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Pritts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2019.113027_bib0005","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.jpba.2019.113027_bib0010","first-page":"329","article-title":"The next generation of antibody-drug conjugates comes of age","volume":"10","author":"Beck","year":"2010","journal-title":"Discov. Med."},{"key":"10.1016\/j.jpba.2019.113027_bib0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/PPO.0b013e318172d704","article-title":"Antibody-drug conjugates for cancer therapy","volume":"14","author":"Carter","year":"2008","journal-title":"Cancer J."},{"key":"10.1016\/j.jpba.2019.113027_bib0020","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.coph.2005.04.008","article-title":"Arming antibodies for cancer therapy","volume":"5","author":"Polakis","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jpba.2019.113027_bib0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","article-title":"Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jpba.2019.113027_bib0030","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jpba.2019.113027_bib0035","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1395127","article-title":"Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)","volume":"7","author":"Hoffmann","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jpba.2019.113027_bib0040","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2019.113027_bib0045","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1021\/bc200212a","article-title":"Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats","volume":"22","author":"Boswell","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jpba.2019.113027_bib0050","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/bc500189z","article-title":"Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes","volume":"25","author":"Drake","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jpba.2019.113027_bib0055","doi-asserted-by":"crossref","first-page":"16101","DOI":"10.1073\/pnas.1211023109","article-title":"Synthesis of site-specific antibody-drug conjugates using unnatural amino acids","volume":"109","author":"Axup","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jpba.2019.113027_bib0060","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/bc400490z","article-title":"Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system","volume":"25","author":"Zimmerman","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jpba.2019.113027_bib0065","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1021\/bc400217g","article-title":"A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology","volume":"24","author":"Jeffrey","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jpba.2019.113027_bib0070","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jpba.2019.113027_bib0075","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-04-779389","article-title":"Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies","author":"Ryan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2019.113027_bib0080","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2019.113027_bib0085","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.1158\/1078-0432.CCR-04-1134","article-title":"Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma","volume":"10","author":"DiJoseph","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2019.113027_bib0090","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpba.2019.113027_bib0095","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jps.24338","article-title":"Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates","volume":"104","author":"Wiggins","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2019.113027_bib0100","first-page":"1210","article-title":"In-depth structural characterization of Kadcyla(R) (ado-trastuzumab emtansine) and its biosimilar candidate","volume":"8","author":"Chen","year":"2016","journal-title":"MabsAustin"},{"key":"10.1016\/j.jpba.2019.113027_bib0105","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2019.113027_bib0110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.chroma.2018.12.020","article-title":"Is hydrophobic interaction chromatography the most suitable technique to characterize site-specific antibody-drug conjugates?","volume":"1586","author":"D\u2019Atri","year":"2019","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2019.113027_bib0115","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jchromb.2017.06.005","article-title":"Characterization of drug load variants in a thiol linked antibody-drug conjugate using multidimensional chromatography","volume":"1060","author":"Gilroy","year":"2017","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2019.113027_bib0120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpba.2016.01.037","article-title":"Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate species in hydrophobic interaction chromatoraphy, part 2: optimization of the phase system","volume":"121","author":"Cusumano","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.113027_bib0125","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpba.2015.11.011","article-title":"Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate species in hydrophobic interaction chromatography, part 1: optimization of the mobile phase","volume":"118","author":"Rodriguez-Aller","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.113027_bib0130","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/bit.22313","article-title":"Hydrophobic interaction chromatography in dual salt system increases protein binding capacity","volume":"103","author":"Senczuk","year":"2009","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jpba.2019.113027_bib0135","series-title":"GE Healthcare","first-page":"1","article-title":"Hydrophobic interaction and reversed phase chromatography - principles and methods","author":"Phase","year":"2019"},{"key":"10.1016\/j.jpba.2019.113027_bib0140","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1021\/ac203346c","article-title":"Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues","volume":"84","author":"Valliere-Douglass","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2019.113027_bib0145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jpba.2017.06.006","article-title":"Comparison of SEC and CE-SDS methods for monitoring hinge fragmentation in IgG1 monoclonal antibodies","volume":"145","author":"Dada","year":"2017","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519319764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519319764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:57:13Z","timestamp":1760000233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519319764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":29,"alternative-id":["S0731708519319764"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.113027","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydrophobic interaction chromatography (HIC) method development and characterization of resolved drug-load variants in site-specifically conjugated pyrrolobenzodiazepine dimer-based antibody drug conjugates (PBD-ADCs)","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.113027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113027"}}